PRION DISEASE. OPHTHALMIC SYMPTOMS (A LECTURE)

  • Authors: Shnayder N.A1, Guseva M.R2
  • Affiliations:
    1. State budgetary educational institution of higher professional education «Krasnoyarsk State Medical University named after Prof. V.F. Voyno-Yasenetsky», Ministry of Health of the Russian Federation
    2. State budgetary educational institution of higher professional education «N.I. Pirogov Russian National Research Medical University», Ministry of Health of the Russian Federation
  • Issue: Vol 9, No 1 (2014)
  • Pages: 64-75
  • Section: Articles
  • URL: https://journals.eco-vector.com/1993-1859/article/view/37612
  • Cite item

Abstract


The prion diseases are a large group of related neurodegenerative conditions, which affect both animals and people. They include Creutzfeldt-Jakob disease and Gerstmann-Straussler-Scheinker, fatal familial insomnia, kuru in humans; bovine spongiform encephalopathy, or mad cow disease, in cattle; and scrapie in sheep etc. All these diseases have long incubation periods, but they are typically rapidly progressive once clinical symptoms begin. All prion diseases have common early manifested ophthalmic symptoms. All prion diseases are fatal, with currently no effective form of treatment. However, increased understanding of their pathogenesis has recently led to the promise of effective prevalence and therapeutic interventions in the near future.

Full Text

Restricted Access

About the authors

N. A Shnayder

State budgetary educational institution of higher professional education «Krasnoyarsk State Medical University named after Prof. V.F. Voyno-Yasenetsky», Ministry of Health of the Russian Federation


M. R Guseva

State budgetary educational institution of higher professional education «N.I. Pirogov Russian National Research Medical University», Ministry of Health of the Russian Federation


References

  1. Bacchetti P. Age and variant Creutzfeldt-Jakob disease. Emerg. Infect. Dis. 2003; 9: 1611—2.
  2. Will R. Epidemiology of Creutzfeldt—Jakob disease. Br.Med.Bull. 1993; 49 (4): 960—70.
  3. Зуев В.А., Завалишин И.А., Ройхель В.М. Прионные болезни человека и животных. М.: Медицина; 1999.
  4. Шнайдер НА. Болезнь Крейтцфельдта—Якоба: новый взгляд на старую проблему (история изучения, этиология и патогенез). Журнал неврологии и психиатрии им. С.С. Корсакова. 2013; 113 (3): 72—9.
  5. Шнайдер НА. Болезнь Крейтцфельдта—Якоба: новый взгляд на старую проблему (история изучения, этиология и патогенез). Журнал неврологии и психиатрии им. С.С. Корсакова. 2013; 113 (4): 61—9.
  6. Collins S.J., Lawson VA., Masters C.L. Transmissible spongiform encephalopathies. Lancet. 2004; 363: 51—61.
  7. Meggendorfer F. Klinische und genealogische Beobachtungen bei einem Fall von spastischer Pseudokosklerose Jakobs. Z. ges. Neurol. Psychiatrie. 1930; 128: 337—41.
  8. VanRheede T., Smolenaar sM.M.W., Madsen O., Jong W.W. Molecular evolution of the mammalian prion protein. Mol. Biol. Evol. 2003; 20: 111—21.
  9. Gajdusek D.C., Zigas V. Degenerative disease of the central nervous system in New Guinea: the epidemic occurrence of «kuru» in the native population. N. Engl. J. Med. 1957; 257: 974—8.
  10. Brown P. Environmental causes of human spongiform encephalopathy. In: Baker H., Ridley R., eds. Prion Diseases. 1996: 139—45.
  11. Brown P., Preece M., Will R. «Friendly fire» in medicine: hormones, homografts, and Creutzfeldt-Jakob disease. Lancet. 1992; 340 (4): 24—7.
  12. Lasmezas C.I., Deslys J-P., Demaimay R., Adjou K.T. et al. BSE transmission to macaques. Nature. 1996; 381: 743—4.
  13. Seipelt M., Zerr I., Nau R. Hashimoto’s encephalitis as a differential diagnosis of Creutzfeldt- Jakob disease. J. Neurol. Neurosurg. Psychiatry. 1999; 66 (2): 172—6.
  14. Collinge J., BeckJ., Campbell T. et al. Prion protein gene analysis in new variant cases of Creutzfeldt-Jakob disease. Lancet. 1996; 348: 56.
  15. Collinge J., Sidle K., Meads J. et al. Molecular analysis of prion strain variation and the aetiology of ‘new variant’ CJD. Nature. 2003; 383 (24): 685—90.
  16. Prusiner S.B. Molecular biology of prion disease. Science. 1991; 252: 1515—22.
  17. Prusiner S.B. Novel proteinaceous infectious particle cause scrapie. Science. 1982; 216: 136—44.
  18. Prusiner S.B. Prion diseases and the BSE crisis. Science. 1997; 278: 245—51.
  19. Шкудина И.С., Тер-Аванесян М.Д. Прионы. Успехи биологической химии. 2006; 46: 403—23.
  20. Гусев Н.Б. Нейродегенеративные болезни и проблема правильного сворачивания белка. Соросовский образовательный журнал. 2004; 8 (2): 15—23.
  21. Jackson G.S., Collinge J. The molecular pathology of CJD: Old and new variants. J. Clin. Pathol.: Mol. Pathol. 2001; 54: 393—9.
  22. Update on BSE. Royal Society — The UK Academy of Science; 1997.
  23. Foster P.R. Prions and blood products. Ann. Med. 2000; 32 (7): 501—13.
  24. Fischer M., Roecki C., Parizek P. et al. Binding of disease-associated prion protein to plasminogen. Nature. 2000; 408 (23): 479—83.
  25. Holman R.C., Khan A.S., Belay E.D: Creutzfeldt-Jakob disease in the United States, 1979—1994: using national mortality data to assess the possible occurrence of variant cases. Emerg. Infect. Dis. 1996; 2 (4): 333—7.
  26. Виноградова Р.П., Бердишев Г.Д., Верьовка С.В. Біохімія та генетика білків пріонів, збудників губкоподібних енцефалопатій. Київ: Фітосоціоцентр; 2000: 9—10.
  27. Покровский В., Киселев О. Молекулярные основы прионовых болезней. Вестник РАМН. 1998; 10: 45—55.
  28. Weismann C., Bueler H., Sailer A. et al. Role of PrP in prion disease. Brit. Med. Bull. 1993; 49 (4): 995—1011.
  29. Forloni G., Angeretti N., Chiesa R. et al. Neurotoxity of a prion protein fragment. Nature. 1993; 362 (8): 543—6.
  30. Weissmann C. Molecular genetics of transmissible spongiform encephalopathies. J. Biol. Chem. 1999; 274: 3—6.
  31. Гусев Е.И., Никифоров А.С. Неврологические симптомы, синдромы и болезни. М.: ГЭОТАР-Медиа; 2006.
  32. Никифоров А.С., Гусева М.Р. Нейроофтальмология. М.: ГЭО-ТАР-Медиа; 2008.
  33. WillR.G.,Ironside J.W., ZeidlerM., et al: A new variant of Creutzfeldt-Jakob disease in the UK. Lancet. 1996; 347 (9006): 921—5.
  34. Payne R., Krakauer D. The paradoxal dynamics of prion disease latency. J. Theor. Biol. 1998; 191 (4): 352—4.
  35. Bacchetti P. Unexamined assumptions in explorations of upper limit for cases of variant Creutzfeldt-Jakob disease. Lancet. 2001; 357: 3—4.
  36. Belay E.D., Schonberger L.B. Variant Creutzfeldt—Jakob disease and bovine spongiform encephalopathy. Clin. Lab. Med. 2002; 22 (4): 849—62. Российская педиатрическая офтальмология, №1, 2014
  37. Hill A.F., Zeidler M., Ironside J., Collinge J. Diagnosis of new variant Creutzfeldt-Jakob disease by tonsil biopsy. Lancet. 1997; 349: 99—100.
  38. Peden A.H., Head M.W., Ritchie D.L. et al. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet. 2004; 364: 527—9.
  39. Rettner R. Blood test may screen for human form of mad cow. MSNBC. 2011.
  40. Ironside J.W., Bell J.E. The ‘high-risk’ neuropathological autopsy in AIDS and Creutzfeldt-Jakob disease: principles and practice. Neuro-pathol. Appl. Neurobiol. 1996; 5: 388—93.
  41. Darbord J. Inactivation of prions in dialy medicine practice. Biomed. and Pharmacother. 1999; 53 (1): 34—8.
  42. Deslys J., Comoy E., Hawkins S. et al. Screening slaughtered cattle for BSE. Nature. 2001; 409 (25): 476—8.
  43. Aguzzi A., Polymenidou M. Mammalian prion biology: One century of evolvingconcepts. Cell. 2004; 116: 313—27.
  44. Winklhofer K., Hartl U., Tazelt J. A sensitive filter retention assay for the detection of PrPSc and the screening of anti-prion compounds. FEBS Lett. 2001; 503 (1): 41—5.
  45. Berg L. Insights into the role of the immune-system in prion diseases. Proc. Natl. Acad. Sci. USA. 1994; 91 (2): 429—32.
  46. Bacchetti P. Uncertainty due to model choice in variant Creutzfeldt-Jakob disease projections. Stat. Med. 2005; 24: 83—93.
  47. Pfeifer A., Eigenbrod S., Al-Khadra S. Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected mice. J. Clin. Investigation. 2006; 116 (12): 3204—10.
  48. Chadeau-Hyam M., Alperovitch A. Risk of variant Creutzfeldt-Jakob disease in France. Int. J. Epidemiol. 2005; 34: 46—52.
  49. Llewelyn C.A., Hewitt P.E., Knight R.S. et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet. 2004; 363: 417—21.
  50. Zerr I., Brandel J.P., Masullo C. et al. European surveillance on Creutzfeldt-Jakob disease: a case-control study for medical risk factors. J. Clin. Epidemiol. 2000; 53: 747—54.
  51. German Federal Ministry of Health Working Group. Overall blood supply strategy with regard to variant Cruetzfeldt-Jakob disease (vC-JD). Transfus. Med. Hemother. 2006; 33 (2): 1—39.

Statistics

Views

Abstract - 8

PDF (Russian) - 0

Cited-By


Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies